Trial Profile
A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Solid Tumors or Lymphomas With Injectable Neoplastic Lesions
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs AvidinOx-Lu-177-DOTA-Biotin (Primary) ; Lutetium-177 biotin-DOTA (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Alfasigma; sigma-tau SpA
- 01 Jul 2019 Status changed from recruiting to discontinued.
- 08 Mar 2019 Planned End Date changed from 1 Jun 2019 to 30 Jul 2019.
- 08 Mar 2019 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.